Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment

R. Ghidoni, L. Benussi, M. Glionna, M. Franzoni, D. Geroldi, E. Emanuele, G. Binetti

Research output: Contribution to journalArticlepeer-review

Abstract

Growing evidence advanced the idea that the soluble form of the receptor for advanced glycation end-products (sRAGE) might serve as a risk marker for several disorders including Alzheimer disease. We found a reduced level of circulating sRAGE in patients with mild cognitive impairment (MCI). The reduction of sRAGE in MCI, as well as the anticipation of the disease in patients with the lowest sRAGE levels (≤225 pg/ml), suggest a role of the RAGE axis in the pathogenesis of the disease.

Original languageEnglish
Pages (from-to)1047-1050
Number of pages4
JournalJournal of Neural Transmission
Volume115
Issue number7
DOIs
Publication statusPublished - Jul 2008

Keywords

  • AD
  • Biological marker
  • Cognitive decline
  • Mild cognitive impairment
  • Plasma
  • sRAGE

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment'. Together they form a unique fingerprint.

Cite this